×
About 3,865 results

ALLMedicine™ Bacterial Pneumonia Center

Research & Reviews  1,629 results

Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905759
Drugs Heo YA

Feb 25th, 2021 - Imipenem/cilastatin/relebactam (Recarbrio™) is an intravenously administered combination of the carbapenem imipenem, the renal dehydropeptidase-I inhibitor cilastatin, and the novel β-lactamase inhibitor relebactam. Relebactam is a potent inhibito...

Dysnatremia is a predictor for morbidity and mortality in hospitalized patients with CO...
https://doi.org/10.1210/clinem/dgab107
The Journal of Clinical Endocrinology and Metabolism; Tzoulis P, Waung JA et. al.

Feb 24th, 2021 - Dysnatremia is an independent predictor of mortality in patients with bacterial pneumonia. There is paucity of data about the incidence and prognostic impact of abnormal sodium concentration in patients with coronavirus disease 19 (COVID-19). This...

Duration of antibiotic therapy in systemic lupus erythematosus patients with hospital-a...
https://doi.org/10.21037/apm-20-584
Annals of Palliative Medicine; Zhu C, Li Y et. al.

Feb 22nd, 2021 - To investigate the duration of antibiotic therapy and its influencing factors in treating systemic lupus erythematosus (SLE) patients with hospital-acquired bacterial pneumonia (HABP). Clinical data of SLE patients with HABP from January 2015 to D...

see more →

Guidelines  7 results

Shared Decision-Making for Administering PCV13 in Older Adults
https://www.aafp.org/afp/2020/0201/p134.html
American Family Physician; Shah AA,et al

Jan 31st, 2020 - Streptococcus pneumoniae infection, the most common cause of bacterial pneumonia, leads to significant morbidity and mortality in older people. With the addition of the pneumococcal conjugate vaccine to childhood immunization schedules in 2000, he...

Melinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
http://ir.melinta.com/news-releases/news-release-details/melinta-therapeutics-announces-us-fda-approval-supplemental-new

Oct 23rd, 2019 - Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced the U.S. Food and Drug Administration (FDA) has appr...

Improving Conduct and Feasibility of Clinical Trials to Evaluate Antibacterial Drugs to...
https://doi.org/10.1093/cid/ciw258
Clinical Infectious Diseases : an Official Publication Of... Knirsch C, Alemayehu D et. al.

Aug 2nd, 2016 - The etiology of hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP) is often multidrug-resistant infections. The evaluation of new antibacterial drugs for efficacy in this population is important, as many antibacterial drugs...

Streamlining Safety Data Collection in Hospital-Acquired Bacterial Pneumonia and Ventil...
https://doi.org/10.1093/cid/ciw316
Clinical Infectious Diseases : an Official Publication Of... Donnelly H, Alemayehu D et. al.

Aug 2nd, 2016 - Resistant bacteria are one of the leading causes of hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP). HABP/VABP trials are complex and difficult to conduct due to the large number of medical procedures, adverse events, and c...

XENLETA™ (lefamulin) Website for Healthcare Professionals
https://www.xenleta.com/

community-acquired bacterial pneumonia See XENLETA™ (lefamulin) clinical trial results and product attributes

see more →

Drugs  139 results see all →

Clinicaltrials.gov  1,895 results

Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905759
Drugs Heo YA

Feb 25th, 2021 - Imipenem/cilastatin/relebactam (Recarbrio™) is an intravenously administered combination of the carbapenem imipenem, the renal dehydropeptidase-I inhibitor cilastatin, and the novel β-lactamase inhibitor relebactam. Relebactam is a potent inhibito...

Dysnatremia is a predictor for morbidity and mortality in hospitalized patients with CO...
https://doi.org/10.1210/clinem/dgab107
The Journal of Clinical Endocrinology and Metabolism; Tzoulis P, Waung JA et. al.

Feb 24th, 2021 - Dysnatremia is an independent predictor of mortality in patients with bacterial pneumonia. There is paucity of data about the incidence and prognostic impact of abnormal sodium concentration in patients with coronavirus disease 19 (COVID-19). This...

Duration of antibiotic therapy in systemic lupus erythematosus patients with hospital-a...
https://doi.org/10.21037/apm-20-584
Annals of Palliative Medicine; Zhu C, Li Y et. al.

Feb 22nd, 2021 - To investigate the duration of antibiotic therapy and its influencing factors in treating systemic lupus erythematosus (SLE) patients with hospital-acquired bacterial pneumonia (HABP). Clinical data of SLE patients with HABP from January 2015 to D...

see more →

News  193 results

How the COVID Pandemic May End: Lessons From the 1918 Flu
https://www.medscape.com/viewarticle/940788

Nov 11th, 2020 - Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. The Spanish flu hit in the fall of 1918; a second surge occurred from January to April 1919, and a smaller one followed in the winter of 1920. Forty million peop...

As COVID-19 Cases Spike, Pneumonia Vaccine Demand Rockets and Europe Runs Low
https://www.staging.medscape.com/viewarticle/939667

Oct 25th, 2020 - MILAN/FRANKFURT/NEW YORK (Reuters) - As COVID-19 infections rise, people seeking to avoid one lung disease compounding another are queuing up to get inoculated against bacterial pneumonia, causing shortages of a Merck & Co vaccine in parts of Euro...

Fast Five Quiz: Pneumonia Key Aspects
https://reference.medscape.com/viewarticle/922410_2

Mar 22nd, 2020 - Physical examination findings may vary depending on the type of organism, severity of infection, coexisting host factors, and presence of complications. Signs of bacterial pneumonia may include the following: Hyperthermia (fever, typically > 38°C)...

Fast Five Quiz: Pneumonia Key Aspects
https://reference.medscape.com/viewarticle/922410

Mar 22nd, 2020 - Bacterial pneumonia is caused by a pathogenic infection of the lungs and may present as a primary disease process or as the final, fatal disorder, primarily in an individual who is already debilitated. Community-acquired pneumonia (CAP) is one of ...

Shared Decision-Making for Administering PCV13 in Older Adults
https://www.aafp.org/afp/2020/0201/p134.html
American Family Physician; Shah AA,et al

Jan 31st, 2020 - Streptococcus pneumoniae infection, the most common cause of bacterial pneumonia, leads to significant morbidity and mortality in older people. With the addition of the pneumococcal conjugate vaccine to childhood immunization schedules in 2000, he...

see more →

Patient Education  2 results see all →